Research on the Heart-Brain Coupling Mechanisms and Interventions for Emotional Inhibitory Control Deficits in Individuals With Alcohol Use Disorder
- Conditions
- Alcohol Use Disorder (AUD)
- Registration Number
- NCT07036055
- Lead Sponsor
- Shanghai Mental Health Center
- Brief Summary
The goal of this clinical trial is to understand whether combining transcutaneous auricular vagus nerve stimulation (taVNS) with mindfulness training can improve emotional inhibitory control in adults with Alcohol Use Disorder (AUD). The study also aims to explore the brain-heart coupling mechanisms underlying these control deficits.
The main questions it aims to answer are:
Do individuals with AUD have abnormal brain-heart coupling associated with impaired emotional inhibitory control? Can taVNS combined with mindfulness training enhance emotional inhibitory control in individuals with AUD compared to sham stimulation? Researchers will compare a group receiving taVNS plus mindfulness training to a group receiving sham stimulation plus mindfulness training to see whether the active intervention improves behavioral performance and brain-heart coupling.
Participants will:
Complete an emotional Go/NoGo task while EEG and ECG data are recorded Receive 10 days of either real or sham taVNS combined with mindfulness training Complete questionnaires and cognitive assessments before and after the intervention
- Detailed Description
This two-part clinical study investigates the mechanisms and intervention effects related to emotional inhibitory control deficits in individuals with Alcohol Use Disorder (AUD), with a specific focus on brain-heart coupling (also referred to as brain-heart interplay, BHI). The study aims to identify the neurophysiological characteristics underlying inhibitory control impairments in AUD and evaluate whether non-invasive vagus nerve stimulation combined with mindfulness training can enhance emotional regulation and cognitive function.
Study 1: Mechanism Exploration Study 1 adopts a case-control observational design. A total of 28 individuals diagnosed with AUD (based on DSM-5 criteria) and 28 age- and education-matched healthy controls are recruited. Participants complete an emotional Go/NoGo task under EEG-ECG hyperscanning. Emotional inhibitory control performance is assessed through behavioral indices (reaction time, error rate) and further analyzed using the Hierarchical Drift Diffusion Model (HDDM) to quantify latent cognitive processing parameters (e.g., drift rate, boundary separation, non-decision time). Brain-heart coupling is evaluated through resting-state EEG-ECG data using multiscale coupling coefficients and maximal information coefficient (MIC) between heart rate variability (HRV) and cortical oscillations (particularly α, β, and θ bands).
Primary outcomes include:
Drift rate and inhibitory control accuracy under emotional interference Degree of BHI (HRV-EEG coupling strength and directionality) The moderating effect of self-reported emotion regulation ability (measured via DERS)
Study 2: Intervention Evaluation
Study 2 is a single-blind randomized controlled trial (RCT) involving 60 AUD participants randomly assigned to:
Active group (n=30): taVNS combined with mindfulness training Control group (n=30): sham stimulation combined with mindfulness training Participants in both groups receive daily 30-minute sessions for 10 consecutive days. taVNS is delivered using a wearable ear-clip device targeting the auricular branch of the vagus nerve (cymba conchae), with stimulation parameters set at 25 Hz, pulse width of 200 μs, and intensity adjusted to individual sensory threshold. Mindfulness training is conducted by a trained therapist, focusing on breath awareness and body scanning.
Outcome measures are collected pre- and post-intervention and include:
Emotional inhibitory control performance under the Go/NoGo paradigm HDDM-derived cognitive parameters (e.g., drift rate) EEG-ECG-based BHI metrics (HRV-EEG coupling during rest) Self-reported anxiety (GAD-7), depressive symptoms (PHQ-9), and alcohol craving Adverse events monitoring and adherence logs Data Acquisition and Processing EEG signals are recorded using a 64-channel portable system (10-20 system); ECG is simultaneously recorded.
Signals are preprocessed in EEGLAB (bandpass filtering, artifact correction via ASR), with HRV features extracted via Kubios.
HDDM modeling is conducted in Python (Bayesian MCMC estimation), and BHI is analyzed through mutual information, MIC, and transfer entropy metrics.
Sample Size and Statistical Plan Sample size was estimated based on prior effect sizes observed in similar taVNS and mindfulness interventions. Power analysis indicated 28 subjects per group achieves \>80% power to detect moderate group × time interaction effects.
Statistical analyses include:
Mixed-effects ANOVA for behavioral and neural outcomes Regression models to assess mediation and moderation effects (e.g., emotion regulation ability) Pearson/Spearman correlation between physiological and behavioral measures All analyses follow intention-to-treat principles with imputation for missing data where appropriate (e.g., multiple imputation for \<10% missing).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 60
- Meets DSM-5 diagnostic criteria for Alcohol Use Disorder (AUD).
- Aged 18-55 years.
- Currently in the post-acute withdrawal phase (≥2 weeks since last alcohol use).
- No severe psychiatric comorbidities (e.g., schizophrenia, bipolar disorder).
- No neurological disorders (e.g., epilepsy, traumatic brain injury).
- Willing to provide informed consent.
- Dependence on other substances (except nicotine).
- Severe physical illness requiring immediate treatment.
- Active infectious diseases (e.g., HIV, hepatitis).
- Inability to complete study procedures (e.g., cognitive impairment).
*(For healthy controls in Study 1, inclusion required AUDIT score ≤8, no psychiatric/neurological history, and matched demographics.)*
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Emotional Inhibitory Control Performance in Emotional Go/NoGo Task Assessed at baseline (Day 0) and post-intervention (Day 11) Emotional inhibitory control performance will be assessed based on participants' accuracy in the emotional Go/NoGo task (i.e., proportion of correctly inhibited responses on NoGo trials). The task uses emotionally valenced facial stimuli and requires participants to withhold responses under emotional interference. Accuracy reflects participants' inhibitory control under affective load, which is the primary behavioral index of intervention efficacy.
- Secondary Outcome Measures
Name Time Method Drift Rate Estimated by Hierarchical Drift Diffusion Model (HDDM) Assessed at baseline (Day 0) and post-intervention (Day 11) Drift rate, a latent parameter derived from the HDDM, reflects the efficiency of cognitive processing and evidence accumulation during the Go/NoGo task. Higher drift rate indicates more efficient response selection under emotional conflict. HDDM modeling is conducted using trial-level reaction time and accuracy data.
Brain-Heart Coupling Strength (HRV-EEG Coupling) Assessed at baseline (Day 0) and post-intervention (Day 11) Degree of brain-heart coupling is measured by calculating multiscale mutual information and maximal information coefficient (MIC) between heart rate variability (HRV) and EEG oscillations (particularly in the alpha, beta, and theta bands) during resting-state data collection. Higher coupling indicates stronger brain-autonomic integration.
Self-Reported Emotion Regulation Ability (DERS Score) Assessed at baseline (Day 0) and post-intervention (Day 11) Participants complete the Difficulties in Emotion Regulation Scale (DERS), which provides a total score and subscale scores reflecting emotional awareness, impulse control, and clarity. Lower scores reflect better emotion regulation capacity.
Alcohol Craving (Visual Analog Scale) Assessed at Day 0, Day 3, Day 6, Day 11 Alcohol craving is measured using a visual analog scale (VAS, 0-100), with higher scores indicating stronger desire to consume alcohol. This outcome reflects emotional-behavioral change after intervention.
Trial Locations
- Locations (1)
China
🇨🇳Mengzi, Yunnan, China
China🇨🇳Mengzi, Yunnan, China